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ABSTRACT
Objectives: Migraine is the second most common type of headache and seventh most disabling disease worldwide. In general, obesity is often related 
to headache disorders in several clinical and epidemiologic studies. Obese migraine patients may have an increased attack frequency due to the 
increase in inflammatory response. Cognitive decline is present in several migraine patients. However, some researchers differ. Body mass index (BMI) 
is also seen to have a role in migraine. This study has been done (i) to define whether cognitive decline is present in a significant degree in migraine 
patients and also (ii) to test whether an association exists between migraine and BMI.
Methods: The study protocol was approved by the ethical committee of SRM Medical College Hospital and Research Centre. The study group consisted 
of 30 migraine patients and 30 healthy controls aged between 18 and 40 years of age. Informed consent was obtained from all the participants. The 
diagnosis of migraine was made using the criteria of the 2nd edition of International Headache Classification. Patients affected by diabetes mellitus, 
hypertension, allergy, inflammation, infection, or immune disorders were excluded from the study to avoid confounding etiology. Height and weight of 
the subjects were taken to calculate the BMI. Cognitive tests such as Stroop interference trial and trial-making tests (A and B) were done to evaluate 
working memory, mental flexibility, and attention.
Results: Compared to controls, cases took more time for performing Stroop color card test (106.40±15.87 seconds vs. 132.17±7.027 seconds, 
p<0.001) and trial-making pattern B (54.77±8.169 seconds vs. 56.23±23.457 seconds, p=0.004). Among the migraine subjects, obese individuals had 
an increased frequency of migraine attack per month (correlation coefficient r=0.797).
Conclusion: In this study, we have found a linear increase in the frequency of migraine in persons with higher BMI. Moreover, migraine subjects 
had a decline in cognitive function in our study, and it is found to be statistically significant. Identifying cognitive decline early can prevent major 
consequences in day-to-day activities of migraine patients. Since there is an increased frequency of migraine with increase in BMI, obese migraine 
subjects can be recommended to do regular exercises.
Keywords: Migraine, Cognition, Stroop test, Obesity.
INTRODUCTION
Migraine is a common neurological disorder, and it is responsible for 
almost 3% of disease burden according to the Global Burden of Disease 
Study of 2010 [1]. It is a markedly disabling condition and exerts a 
significant burden on the sufferer in terms of pain, suffering, and 
impaired quality of life [2]. Obesity and migraine are the two common 
health problems which at times may interlink [3]. Previous studies 
suggest an association between migraine and obesity. Obesity may 
affect the frequency of migraine attacks per month and cause crippling 
headaches [4,5]. The mechanism behind obesity and migraine remains 
unclear. Growing evidence suggests that there could be an increase in 
inflammatory response mainly due to the release of proinflammatory 
cytokines in obesity which triggers the migraine attack [6]. Neurogenic 
inflammation causes release of tumor necrosis factor-alpha (TNF-α) 
and interleukin-6 (IL-6) [7,8]. The levels of these cytokines were found 
to be increased in migraine [9]. Elevated levels of TNF-α and IL-6 may 
have an adverse effect on synaptic plasticity and cognition. Migraine 
and obesity are said to be associated with increased TNF-α and IL-6. 
Further increased frequency of migraine attack in obesity may tend 
to accelerate cognitive decline. As the data from previous studies 
in determining cognition among migraine patients are scarce, we 
intended to do this study on cognition in migraine and its association 
with obesity.
METHODS
After obtaining the Institutional Ethical Clearance, an observational 
case–control study was conducted in a private medical hospital. The 
study duration was about 9 months, conducted from September 2015 to 
June 2016. Thirty migraine subjects who attended neurology outpatient 
department and 30 individuals aged between 18 and 40 years were 
recruited in this study. Informed consent was obtained from all the 
participants. Diagnosis of migraine was made using the criteria of 
the 2nd edition of International Headache Classification [10]. Patients 
affected by diabetes mellitus, hypertension, allergy, inflammation, 
infection, or immune disorders were excluded from the study. Height 
and weight of the subjects were taken to calculate the body mass index 
(BMI).
Cognitive tests such as Stroop interference trial and trial-making tests 
(A and B) were done to evaluate working memory, mental flexibility, 
and attention. Stroop interference trial comprises of three cards A, 
B, and C. Card A (color card) contains 100 patches of three different 
colors, Card B (word card) contains names of the colors printed in 
black and white, and Card C (color-word card) contains the name of the 
color printed in a conflicting color ink (e.g., red color may be printed in 
blue or green color ink). The subject’s (S’s) task on card A is simply to 
utter the names of the colored patches as rapidly as possible, scanning 
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the rows left to right. On card B, the S reads aloud the color names as 
rapidly as possible. On card C, the S is required to name the colors of the 
inks while ignoring the conflicting printed color names. The S’s basic 
score on each card is the total time (in seconds) he/she takes to utter 
the 100 names [11].
Trial-making pattern A is a chart consists of series of numerical 
arranged in a jumbled manner. The subject has to join the numbers 
in ascending order without lifting the pen as soon as possible. Trial-
making pattern B is a chart consists numerical and alphabets arranged 
in a jumbled manner. The subject has to join the numbers and alphabets 
in a systematic order, for example, subject has to join 1 to A followed by 
2 and then to B in a sequential order. The time taken to complete the 
task was noted in seconds.
RESULTS
In our study, we have found that there was no significant difference in 
age and BMI between controls and cases (Table 1). We have also found 
that the time taken to complete the cognitive tasks by migraineurs was 
much longer than the controls in trial-making pattern B (p=0.004) and 
Stroop color card test (p=0.000) and they are statistically significant 
(Table 2). We have found a positive correlation between BMI and 
migraine attack frequency per month (r=0.797). As the BMI increases, 
the attack frequency per month also increases (Fig. 1).
Fig. 1 shows the correlation between BMI and frequency of migraine 
among migraineurs.
Fig. 2 shows the schematic illustration of the possible inflammatory 
pathway exists in migraine and obesity on cognition. Previous studies 
have shown that the levels of TNF-α and IL-6 were found to be increased 
in migraine patients. Obesity, a mediator of inflammation, also increases 
the levels of TNF-α and IL-6 which in turn increases the frequency of 
migraine. TNF-α and IL-6 play a significant role in cognition. Increase 
in these two proinflammatory cytokines has a deleterious effect on 
cognition.
DISCUSSION
Overweight and obesity are defined as abnormal or excessive fat 
accumulation that may impair health. Overweight and obesity are 
the fifth leading risk for global deaths. At least 2.8 million adults die 
each year as a result of being overweight or obese [12]. Past studies 
have shown that the frequency of migraine increases with increase 
in BMI [13-15]. In our study also, we have found that there is linear 
increase in the attack frequency as BMI increases, and it is found to be 
statistically significant (Fig. 1). The mechanism behind this correlation 
is very complex. Migraine, as such a disorder of inflammation along 
with obesity, imposes an increased risk of future complications 
by releasing inflammatory cytokines [16,17]. Adipocytes releases 
increased amount of proinflammatory cytokines such as TNF-α, IL-6, 
and IL-1 in migraineurs when compared to healthy controls [18]. 
In obesity too, these inflammatory cytokines are increased which 
causes constant mild inflammation that triggers migraine-related 
inflammatory reactions. This increases the frequency and severity of 
migraine [16].
Interestingly, TNF-α and IL-6 have a beneficial role in memory and 
cognition when they are within the normal limit [19]. Increased levels 
of TNF-α and IL-6 have a deleterious effect on cognition [20,21]. 
Growing evidence suggests that the cytokines IL-6 and TNF-α are 
involved in the molecular and cellular mechanism of complex cognitive 
processes [22,23]. They play a major role in synaptic plasticity, long-
term potentiation, neurogenesis, and memory consolidation. IL-6 and 
TNF-α exert multiple physiological functions within the CNS, which 
are both neuroprotective and neurodegenerative [24]. Increased levels 
of IL-6 cause neural stem cell dysfunction and an associated decline 
in learning and memory [25]. Cognitive impairment has also been 
demonstrated in transgenic mice overexpressing TNF-α [26]. It is due 
to the changes in synaptic plasticity and impairment of long-term 
potentiation which causes neurodegeneration [27].
We have found that there is decline in cognition in migraineurs when 
compared with controls especially in executive functions and mental 
flexibility, and it is statistically significant (Table 2). This could be due 
to the release of inflammatory cytokines which decreases cognition. 
However, we did not find any significant difference in cognition among 
normal weight and obese migraine patients. From this, we can conclude 
that even though obesity increases the frequency of migraine, it does 
Fig. 1: Correlation between body mass index and frequency of 
migraine among migraineurs
Fig. 2: Mechanism of inflammatory pathway
Table 1: Demographic profile of controls and migraine 
patients (cases)
Parameters Mean±SD p value
Control Case
Age (years) 29.30±4.85 28.40±5.29 0.493
BMI (kg/m2) 26.64±3.32 26.40±3.54 0.632
Results are expressed as mean±SD of 30 in each group. SD: Standard deviation, 
BMI: Body mass index
Table 2: Cognitive tests results between controls and migraine 
patients (cases)
Parameters Control (seconds) Case (seconds)
Trial-making pattern A 31.53±13.31 31.77±14.46
Trial-making pattern B 54.77±8.169 56.23±23.457***
Stroop (B/W) 38.2±3.9 50.53±4.98




Results are expressed as mean±SD of 30 in each group; ***p<0.001. 
SD: Standard deviation
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not have a direct effect on cognition in migraine patients. However, 
repeated attacks of migraine may predispose the individual to early 
cognitive decline. Hence, obesity seems to be an independent risk for 
migraine and migraine-related cognitive decline. This is one of the very 
few studies done in young migraine patients, that is, during their most 
productive years.
CONCLUSION
Early identification and prevention of cognitive decline in migraineurs 
will prevent major difficulty in day-to-day activities of the migraine 
subjects. There is an urgent need to emphasis on the maintenance of 
normal BMI to prevent increased attack frequency which in turn further 
declines the cognition much early in life.
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